-
Comparative Review of Avibactam, Vaborbactam, and Relebactam Against Multidrug-Resistant Superbugs
-
Additive Manufacturing, Thermoplastics, CAD, and Reverse Engineering in Orthopedics and Neurosurgery for Infection Prevention and Treatment
-
Vancomycin-Resistant E. faecium: Addressing Global and Clinical Challenges
Journal Description
Antibiotics
Antibiotics
is an international, peer-reviewed, open access journal on all aspects of antibiotics, published monthly online by MDPI. The Croatian Pharmacological Society (CPS) is affiliated with Antibiotics and its members receive discounts on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
- Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
4.6 (2024);
5-Year Impact Factor:
4.9 (2024)
Latest Articles
New Insights in blaKPC Gene Mobilization in Pseudomonas aeruginosa: Acquisition of blaKPC-3 and Identification of a New Tn2-like NTE Mobilizing blaKPC-2
Antibiotics 2025, 14(9), 947; https://doi.org/10.3390/antibiotics14090947 (registering DOI) - 19 Sep 2025
Abstract
Carbapenem-resistant Pseudomonas aeruginosa is a major cause of healthcare associated infections in hospitalized patients and what is more warring with reduced therapeutic options. The KPC is a powerful enzyme capable of hydrolyzing the carbapenems, described first in Klebsiella pneumoniae and it already has
[...] Read more.
Carbapenem-resistant Pseudomonas aeruginosa is a major cause of healthcare associated infections in hospitalized patients and what is more warring with reduced therapeutic options. The KPC is a powerful enzyme capable of hydrolyzing the carbapenems, described first in Klebsiella pneumoniae and it already has found in P. aeruginosa.Objective: To perform a comparative genomic analysis of two new genetic platforms mobilizing the blaKPC-2 and blaKPC-3 in two ST111 and ST235 pandemic clones of P. aeruginosa in Colombia, South America. Methods: Sixty-six blaKPC-harboring P. aeruginosa isolates were identified and characterized during a prospective study conducted in six high complex hospitals in Colombia. Genetic platforms mobilizing the blaKPC were analyzed. Results: The blaKPC-2 and blaKPC-3 were identified in 24 and 42 isolates, respectively. The blaKPC-2-harboring isolates belonged to ST235 and blaKPC-3 to ST111. The whole genome sequencing indicated that the blaKPC-3 gene was mobilized by the Tn4401b within a 55-kb-size environmental origin plasmid, which, in other isolates, was inserted into the chromosome through a transposition event of ISPa38. Regarding the blaKPC-2 gene, this was mobilized by a new Non-Tn4401 Element (NTE) derived from transposon Tn2 (proposed as variant IIg), which has been transposed into a 43-Kb-size little-studied plasmid related to Klebsiella spp. Conclusions: Our results reveal a new acquisition event of blaKPC in P. aeruginosa, in this case blaKPC-3. Likewise, the pandemic high-risk clones ST111 and ST235 of P. aeruginosa continues to spread blaKPC gene through different mobile genetic elements, jumping of conventional Tn4401b and acquiring new Tn2-derived NTE, which were inserted in diverse plasmids.
Full article
(This article belongs to the Section Mechanism and Evolution of Antibiotic Resistance)
►
Show Figures
Open AccessReview
Climate Change and AMR: Interconnected Threats and One Health Solutions
by
Bilal Aslam and Sulaiman F. Aljasir
Antibiotics 2025, 14(9), 946; https://doi.org/10.3390/antibiotics14090946 (registering DOI) - 18 Sep 2025
Abstract
Climate change is a significant driver of antimicrobial resistance (AMR) and infectious disease dynamics, presenting urgent and interconnected global health challenges. Rising temperatures, ecosystem alterations, and extreme weather events amplify the global spread of resistant pathogens, zoonotic infections, and vector-borne diseases. These impacts
[...] Read more.
Climate change is a significant driver of antimicrobial resistance (AMR) and infectious disease dynamics, presenting urgent and interconnected global health challenges. Rising temperatures, ecosystem alterations, and extreme weather events amplify the global spread of resistant pathogens, zoonotic infections, and vector-borne diseases. These impacts disproportionately affect low- and middle-income countries (LMICs), escalating healthcare costs and straining limited infrastructure. A critical characteristic of bacterial resistance is that it often does not incur a fitness cost, underscoring the necessity of preventive strategies to mitigate climate-driven AMR emergence, rather than relying on reactive treatments after resistance is established. Climate change accelerates AMR primarily by increasing the prevalence of infectious diseases, which in turn drive higher antibiotic use and select resistance. The socioeconomic consequences are particularly severe in LMICs, where high climate vulnerability converges with weaker health systems. Pandemic-related disruptions provided key insights into environmental dynamics, with notable temporary reductions in nitrogen dioxide (NO2) emissions, i.e., 20–30% in China, Italy, France, and Spain, and approximately 30% in the USA, which highlights the responsiveness of ecosystems to human activity. Unlike prior reviews that treated AMR and climate change as separate issues, this article integrates mechanistic evidence, epidemiological insights, and global strategies to provide a comprehensive One Health framework addressing these synergistic threats. We conclude that AMR and climate change are interlinked crises requiring urgent, integrated interventions. The quadripartite (FAO, UNEP, WHO, WOAH) provides a crucial framework for the coordinated cross-sectoral strategies, strengthened surveillance, and robust antibiotic stewardship required to mitigate this dual threat and safeguard global health security.
Full article
(This article belongs to the Special Issue Antimicrobial Resistance in the Era of Climate Change)
►▼
Show Figures

Graphical abstract
Open AccessEditorial
Genomic Characterization of Antimicrobial Resistance and Evolution Mechanism of Bacteria
by
Daniel Gyamfi Amoako and Linda Antionette Bester
Antibiotics 2025, 14(9), 945; https://doi.org/10.3390/antibiotics14090945 - 18 Sep 2025
Abstract
Antimicrobial resistance (AMR) continues to rank among the most pressing global health threats, frequently referred to as a “silent pandemic” that undermines decades of progress in infectious disease control while jeopardizing both human and animal health [...]
Full article
(This article belongs to the Special Issue Genomic Characterization of Antimicrobial Resistance and Evolution Mechanism of Bacteria)
Open AccessArticle
Whole-Genome Sequencing and Antibiotic Resistance Profiling of Helicobacter pylori Isolates from a Tertiary Hospital in Southern Thailand
by
Chonticha Romyasamit, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Komwit Surachat, Sirikan Suwannasin, Yosita Leepromma, Morteza Saki, Maseetoh Samaeng and Phoomjai Sornsenee
Antibiotics 2025, 14(9), 944; https://doi.org/10.3390/antibiotics14090944 (registering DOI) - 18 Sep 2025
Abstract
Background: Helicobacter pylori is associated with a wide range of gastroduodenal diseases, including chronic gastritis, peptic ulcer disease, and gastric cancer. Eradication efforts are challenged by increasing antimicrobial resistance rates, particularly in Southeast Asia. We sequenced the whole genomes of clinical H.
[...] Read more.
Background: Helicobacter pylori is associated with a wide range of gastroduodenal diseases, including chronic gastritis, peptic ulcer disease, and gastric cancer. Eradication efforts are challenged by increasing antimicrobial resistance rates, particularly in Southeast Asia. We sequenced the whole genomes of clinical H. pylori isolates from Southern Thailand to elucidate their resistance profiles, virulence determinants, and evolutionary relationships. Methods: Three clinical H. pylori isolates (004, 117, and 189) were subjected to whole-genome sequencing, phenotypic antimicrobial susceptibility testing, and comparative genomic analyses. Results: All strains exhibited high-level resistance to metronidazole. Additionally, H. pylori 117 was resistant to both amoxicillin and levofloxacin, classifying it as multidrug-resistant. Genomic analysis revealed mutations in rdxA, frxA, and rpoB, as well as in penicillin-binding protein genes (pbp2 and pbp3), supporting the phenotypic findings. While all isolates harboured clarithromycin resistance mutations (A2142G and A2143G in the 23S rRNA gene), they were phenotypically susceptible, highlighting a potential discordance that requires further investigation. Virulence gene profiling identified 115–118 conserved genes per strain, including cagA, vacA, oipA, babA, and flagellar, urease, and lipopolysaccharide biosynthesis genes. Phylogenetic analysis using core-genome single-nucleotide polymorphisms demonstrated that these strains formed a distinct Southern Thai monophyletic clade, suggesting localised clonal expansion driven by regional selective pressures. Conclusions: Region-specific surveillance strategies and treatment guidelines are urgently needed in Thailand. The combination of high-risk virulence genes and rising antimicrobial resistance in H. pylori strains necessitates tailored therapeutic approaches, the integration of genomic surveillance into clinical diagnostics, and expanded studies linking genotype to clinical outcomes in diverse populations.
Full article
(This article belongs to the Special Issue Genomic Insights into Dissemination of Multi-Drug Resistance Pathogens)
►▼
Show Figures

Figure 1
Open AccessArticle
Antimicrobial and Antibiofilm Activities of Some Antioxidant 3,4-Dihydroxyphenyl-thiazole-coumarin Hybrid Compounds: In Silico and In Vitro Evaluation
by
Daniel Ungureanu, Gabriel Marc, Mihaela Niculina Duma, Radu Tamaian, Dan Cristian Vodnar, Brîndușa Tiperciuc, Cristina Moldovan, Ioana Ionuț, Anca Stana and Ovidiu Oniga
Antibiotics 2025, 14(9), 943; https://doi.org/10.3390/antibiotics14090943 - 18 Sep 2025
Abstract
Background/Objectives: In this study, we aimed to investigate the antimicrobial and antibiofilm activity of seven hydroxyphenyl-thiazolyl-coumarin hybrid compounds with antioxidant properties (1a–g), previously reported by our group. Methods: The compounds were evaluated in vitro through MIC, MBC,
[...] Read more.
Background/Objectives: In this study, we aimed to investigate the antimicrobial and antibiofilm activity of seven hydroxyphenyl-thiazolyl-coumarin hybrid compounds with antioxidant properties (1a–g), previously reported by our group. Methods: The compounds were evaluated in vitro through MIC, MBC, and MFC determinations, and percentage of biofilm (BF) inhibition and in silico, respectively, through molecular docking, molecular dynamics simulations, and ADMETox prediction. Results: All compounds showed antibacterial and antifungal activities. In terms of antibacterial activity, all the compounds were active on Pseudomonas aeruginosa (MICs = 15.62–31.25 μg/mL), Enterococcus faecalis (MICs = 15.62–31.25 μg/mL), and Staphylococcus aureus (MICs = 62.5–125 μg/mL). Regarding the antifungal activity, the effect against Candida albicans was similar to fluconazole (MIC = 15.62 μg/mL), compounds 1b and 1g being the most active against Aspergillus brasiliensis (MIC = 15.62 μg/mL). Furthermore, all compounds were both bactericidal and fungicidal. Regarding the antibiofilm activity, compounds 1d–g showed superior P. aeruginosa BF inhibition compared to gentamicin. The in vitro results for the antibacterial activity were well correlated with the observations drawn in the molecular docking studies, where the best binding affinities (BAs) were observed against P. aeruginosa PAO1 GyrB subunit, and the molecular dynamics simulations confirmed the antibacterial mechanism of compounds 1a, 1b, 1d, 1f, and 1g through GyrB subunit inhibition. Regarding the antifungal activity, all compounds showed better BAs than fluconazole against CYP51 in all instances. ADMETox predictions concluded that all the compounds could have low gastrointestinal absorption and reduced risk of pharmacokinetic interactions. Conclusions: The investigated compounds bring novelty into the actual research due to their dual antibacterial and antibiofilm activity against biofilm-associated P. aeruginosa infections.
Full article
(This article belongs to the Special Issue Discovery and Design of New Antimicrobial Agents)
►▼
Show Figures

Figure 1
Open AccessArticle
Phage Resistance Modulates Escherichia coli B Response to Metal-Based Antimicrobials
by
Franklin C. Ezeanowai, Akamu J. Ewunkem, Ugonna C. Morikwe, Larisa C. Kiki, Lindsey W. McGee, Joseph L. Graves, Jr. and Liesl K. Jeffers-Francis
Antibiotics 2025, 14(9), 942; https://doi.org/10.3390/antibiotics14090942 - 18 Sep 2025
Abstract
►▼
Show Figures
Background/Objective: The rise of multidrug-resistant bacteria underscores the urgent need for alternative antimicrobial strategies. Metal-based compounds and bacteriophage (phage) therapy have emerged as promising candidates, but the evolutionary trade-offs associated with these selective pressures and their combination remain poorly understood. This study
[...] Read more.
Background/Objective: The rise of multidrug-resistant bacteria underscores the urgent need for alternative antimicrobial strategies. Metal-based compounds and bacteriophage (phage) therapy have emerged as promising candidates, but the evolutionary trade-offs associated with these selective pressures and their combination remain poorly understood. This study aimed to investigate how prior exposure to T4 phage influences Escherichia coli B’s subsequent adaptation to iron (III) stress and to assess the resulting phenotypic and genomic signatures of dual resistance. Method: In this study, we performed experimental evolution using Escherichia coli B to investigate adaptive responses under four conditions: control (LB broth), T4 phage-only, iron (III) sulfate-only, and sequential phage followed by iron (III) exposure. Each treatment consisted of ten independently evolved populations (biological replicates), all derived from a common ancestral strain and passaged daily for 35 days. Phage resistance evolved rapidly, with complete resistance observed within 24 h of exposure. Results: In contrast, iron-selected populations evolved tolerance to high iron concentrations (1000–1750 mg/L) over time at a cost to resistance in other metals (gallium and iron (II) and antibiotics (tetracycline). Notably, prior phage exposure altered these outcomes: phage/iron-selected populations retained phage resistance and iron tolerance but showed diminished resistance to iron (II) and distinct antibiotic sensitivity profiles. Whole-genome sequencing revealed stressor-specific adaptations: large deletions in phage receptor-related genes (waaA and waaG) under phage pressure, and selective sweeps in iron-adapted populations affecting regulatory and membrane-associated genes (qseB, basR, aroK, fieF, rseB, and cpxP). Conclusions: These results demonstrate that the sequence of environmental stressors significantly shapes phenotypic and genetic resistance outcomes. Our findings highlight the importance of fitness epistasis and historical contingency in microbial adaptation, with implications for the design of evolution-informed combination therapies.
Full article

Figure 1
Open AccessArticle
α-Amylase-Mediated Antibiotic Degradation and Sequestration in Pseudomonas aeruginosa Biofilm Therapy
by
Robert K. Murray, Allison E. Martin, Sarah Zipkowitz, Nusrat Jahan, Tony D. Davis and Whitni K. Redman
Antibiotics 2025, 14(9), 941; https://doi.org/10.3390/antibiotics14090941 - 18 Sep 2025
Abstract
Background: As of 2022, 80% of all documented microbial infections are biofilm-associated: communities of microorganisms adhered to a surface and enclosed in a complex extracellular polymeric substance (EPS). The EPS acts as a physical barrier protecting the bacteria from antimicrobial agents and host
[...] Read more.
Background: As of 2022, 80% of all documented microbial infections are biofilm-associated: communities of microorganisms adhered to a surface and enclosed in a complex extracellular polymeric substance (EPS). The EPS acts as a physical barrier protecting the bacteria from antimicrobial agents and host immune responses. To combat this hurdle, the application of glycoside hydrolases (GH) has been investigated due to their ability to cleave particular structural polysaccharides within the EPS, thus breaking down the protective barrier and improving antibiotic clearance. While various studies demonstrate the capacity of GHs to improve antibiotic efficacy against biofilms in combination, there is clear differential success between these treatments depending on the GH and antibiotic chosen. Due to the overlap of GH targets and antibiotic structures, it is imperative to ensure that the antibiotics in combinatorial treatments are not degraded by the GH. Methods: This study aimed to screen the GH α-amylase produced from Aspergillus oryzae (AO) and Bacillus subtilis (BS), combined with various antibiotics from different classes, charges, and mode of actions by determining MICs. against the bacterium Pseudomonas aeruginosa (PA) of 6 antibiotics with or without α-amylase and treat 2-day PA biofilms with antibiotics with or without GHs. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) stability assays and Differential Scanning Fluorimetry (DSF) were conducted to determine antibiotic and GH degradation as well as antibiotic sequestration. Results: Increased MICs in the presence of GHs as well as decreased antibiotic clearance against 2-day biofilms were suggestive of antibiotic degradation. LC-MS/MS stability assays of tetracycline and ciprofloxacin in the presence and absence of α-amylase further demonstrated the α-amylase-mediated antibiotic sequestration. Differential scanning fluorimetry (DSF) assays confirmed α-amylase-antibiotic interactions. Conclusions: This study suggests that α-amylase is capable of degrading and sequestering a variety of antibiotics, and the degree to which these phenomena occur varies depending upon the source of the GH. As a potential treatment for biofilm-associated infections, it is imperative that the GH + antibiotic combinations are determined compatible prior to clinical use.
Full article
(This article belongs to the Special Issue Antimicrobial Resistance in Biofilm-Associated Infections)
►▼
Show Figures

Figure 1
Open AccessSystematic Review
Health Literacy and Interventions on Antibiotics Use and AMR in Younger Generations in High-Income Countries—A Systematic Review
by
Katja Molan, Anamarija Zore and Nevenka Kregar Velikonja
Antibiotics 2025, 14(9), 940; https://doi.org/10.3390/antibiotics14090940 - 17 Sep 2025
Abstract
Antimicrobial resistance (AMR) is a growing threat to global health, accelerated by the widespread inappropriate use of antibiotics. Although educational initiatives have been launched worldwide, there is little evidence on how younger generations in high-income countries (HICs) understand and address AMR. Addressing the
[...] Read more.
Antimicrobial resistance (AMR) is a growing threat to global health, accelerated by the widespread inappropriate use of antibiotics. Although educational initiatives have been launched worldwide, there is little evidence on how younger generations in high-income countries (HICs) understand and address AMR. Addressing the AMR crisis requires proactive education of younger generations, including children, adolescents, and young adults, who will shape future healthcare practices. This review analyzes existing research on AMR literacy among these age groups in HICs, as knowledge gaps and risky behaviors persist even in HICs, despite their strong education and health infrastructures. The purpose of this review is to examine the knowledge, attitudes, and behaviors related to antibiotic use and antibiotic resistance in younger generations while identifying effective educational interventions. Methods: We performed a comprehensive literature search in PubMed until June 2025, followed by AI-assisted screening (Claude 4.0 Sonnet) and a manual review. The search strategy combined terms from the areas of health literacy, antibiotics, antibiotic resistance/AMR, and young populations. Studies in HICs that examined the younger generation’s knowledge about antibiotics and AMR, analyzed their attitudes or behavior toward them, or evaluated relevant educational interventions were included. Data were synthesized thematically across all included studies. Results: Nineteen studies from 11 HICs were included, including thirteen cross-sectional surveys and six educational intervention studies. The results showed that misconceptions about how antibiotics work are still very common. Several of those asked (22–80%) incorrectly stated that resistance develops in the human body and not in bacteria. Many (26–77%) mistakenly agreed with the statement that antibiotics treat viral infections. Concerning behaviors included high rates of self-medication, non-adherence to treatment, and unsafe storage practices. Several authors propose an amendment of curricula. Educational interventions, particularly gamification and peer education approaches, showed improvements in knowledge and sustained learning outcomes. Conclusions: Knowledge of AMR among young people in HICs is still inadequate, despite educational advantages. Most existing studies focus on college students, while children and adolescents, crucial groups for early prevention, are underrepresented. Targeted, age-appropriate education employing interactive methods represents an evidence-based strategy to improve antibiotic use behavior and support global AMR control efforts.
Full article
(This article belongs to the Special Issue Knowledge, Attitudes and Practices of Antimicrobial Resistance and Stewardship in Primary Care Setting: From Understanding to Informing Interventions)
►▼
Show Figures

Figure 1
Open AccessArticle
Optimising Meropenem and Piperacillin Dosing in Patients Undergoing Extracorporeal Membrane Oxygenation Without Renal Dysfunction (MEPIMEX)
by
Mar Ronda, M Paz Fuset, Erika Esteve-Pitarch, Josep Llop, Victor Daniel Gumucio-Sanguino, Evelyn Shaw, Daniel Marco Mula, Kristel Maisterra-Santos, Joan Sabater, Xose L. Pérez, Sara Cobo-Sacristan, Raül Rigo, Fe Tubau, Jordi Carratalà, Helena Colom-Codina and Ariadna Padullés
Antibiotics 2025, 14(9), 939; https://doi.org/10.3390/antibiotics14090939 - 17 Sep 2025
Abstract
Background/Objectives: Antibiotic pharmacokinetics (PK) and pharmacodynamics (PD) are altered during extracorporeal membrane oxygenation (ECMO). Meropenem and piperacillin are among the most commonly prescribed antibiotics for infections in this population. However, guidance on dosage adjustments in the ECMO setting remains limited. We aim
[...] Read more.
Background/Objectives: Antibiotic pharmacokinetics (PK) and pharmacodynamics (PD) are altered during extracorporeal membrane oxygenation (ECMO). Meropenem and piperacillin are among the most commonly prescribed antibiotics for infections in this population. However, guidance on dosage adjustments in the ECMO setting remains limited. We aim to assess differences in meropenem and piperacillin concentrations achieved and identify the clinical, physiological, and mechanical factors influencing antibiotic exposure. Methods: This is a retrospective, single-centre, observational study comparing an ECMO cohort with a population control group from a prior study, without renal dysfunction. Demographic, clinical, PK/PD parameters, and ECMO-related data were analysed using univariate and generalised estimating equations. For both antimicrobials, the PK/PD target was set at 100%fT>4xMIC. Results: A total of 130 critically ill patients were included: 18 in the ECMO group and 112 in the control group. The mean age was 65 years (23), 67% were male and 26.9% were classified as obese. For meropenem, renal function and ECMO support significantly influenced drug exposure, with PK/PD targets being achieved in 67% of measurements; in contrast, piperacillin exposure exhibited greater variability, primarily driven by renal function and mechanical ventilation. Notably, PK/PD targets for piperacillin were met in only 20% of measurements. Conclusions: Our findings highlight the considerable variability in β-lactam exposures and PK/PD target attainment in critically ill patients. This study underscores the importance of therapeutic drug monitoring and individualised dosing in attempts to improve antimicrobial efficacy and patient outcomes in this challenging setting.
Full article
(This article belongs to the Special Issue Antibiotic Stewardship Implementation Strategies)
►▼
Show Figures

Figure 1
Open AccessArticle
Prediction Score for Identification of ESBL Producers in Urinary Infections Overestimates Risk in High-ESBL-Prevalence Setting
by
Jorge Alberto Cortés, Julián Antonio Niño-Godoy and Heidi Johanna Muñoz-Latorre
Antibiotics 2025, 14(9), 938; https://doi.org/10.3390/antibiotics14090938 - 17 Sep 2025
Abstract
Background/Objectives: Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL) Enterobacterales have become more frequent. Therefore, strategies for assessing the risks posed by ESBL-producing infections have been developed, creating the need for local validation. The aim of this study was to validate the
[...] Read more.
Background/Objectives: Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL) Enterobacterales have become more frequent. Therefore, strategies for assessing the risks posed by ESBL-producing infections have been developed, creating the need for local validation. The aim of this study was to validate the scoring system designed by Tumbarello et al. to identify ESBL producers in patients with a UTI that require hospital care in a region with a high prevalence of ESBL Escherichia coli. Methods: A retrospective cohort study was conducted in a third-level hospital in Bogotá (Colombia) between 2013 and 2020.The study included 817 patients, who were hospitalized due to pyelonephritis and treated with cefuroxime (the first-line antibiotic according to local guidelines), with an ESBL frequency of 9.68%. Diagnostic performances were estimated for a modified version of Tumbarello’s score (omitting admission from another healthcare facility) evaluating the area under the curve (AUC) for ESBL presence with respect to resistance to second- and third-generation cephalosporins. Results: With an index cut-off of ≥6, the score showed a sensitivity of 18% and a specificity of 83%. The AUC for this cut-off was 0.47. This threshold index could not efficiently predict either third- (AUC = 0.49) or second-generation cephalosporin resistance (AUC = 0.51). Conclusions: In Colombia, a region with a high prevalence of ESBL E. coli producers, as the use of the Tumbarello index would result in excessive utilization of wide-spectrum antibiotics, it is not recommended in this specific scenario for UTIs. Further studies are required in order to develop accurate tools to assess the risk of ESBL producers in high-prevalence settings.
Full article
(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
►▼
Show Figures

Figure 1
Open AccessArticle
Beyond Culture: Real-Time PCR Performance in Detecting Causative Pathogens and Key Antibiotic Resistance Genes in Hospital-Acquired Pneumonia
by
Lana Hani Abu Khadija, Shatha M. Alomari, Ahmad R. Alsayed, Heba A. Khader, Andi Dian Permana, Luai Z. Hasoun, Manar Saleh Zraikat, Walaa Ashran and Malek Zihlif
Antibiotics 2025, 14(9), 937; https://doi.org/10.3390/antibiotics14090937 - 17 Sep 2025
Abstract
Introduction: The rise in hospital-acquired pneumonia (HAP) due to antibiotic-resistant bacteria is increasing morbidity, mortality, and inappropriate empirical antibiotic use. This prospective research aimed to evaluate the performance of a real-time polymerase chain reaction (PCR) assay for detecting causative microorganisms and antibiotic-resistance genes
[...] Read more.
Introduction: The rise in hospital-acquired pneumonia (HAP) due to antibiotic-resistant bacteria is increasing morbidity, mortality, and inappropriate empirical antibiotic use. This prospective research aimed to evaluate the performance of a real-time polymerase chain reaction (PCR) assay for detecting causative microorganisms and antibiotic-resistance genes from respiratory specimens compared to traditional methods. Additionally, we aimed to determine the molecular epidemiology of antibiotic resistance genes among HAP patients at The University of Jordan hospital. Methods: Lower respiratory tract samples were collected from HAP patients, including those with ventilator-associated pneumonia (VAP), between May 2024 and October 2024. Clinical data from the medical files were used to collect and analyze demographic and clinical information, including clinical outcomes. Real-time PCR was run to detect causative microbes and antibiotic resistance genes. Results: Among 83 HAP patients (median age 63, 61.45% male), 48.15% died. Culture identified Klebsiella (25.53%), Acinetobacter (22.34%), and Candida (24.47%) as the most common pathogens, while qPCR showed higher detection rates, including for A. baumannii (62.20%, p = 0.02) and K. pneumoniae (45.12%, p < 0.001). Carbapenem resistance was high; A. baumannii showed 100% resistance to most antibiotics except colistin (92.31%). The resistance genes ndm (60%) and oxa-48 (58.46%) were frequently detected and significantly associated with phenotypic resistance (p < 0.001). The qPCR identified resistance genes in all carbapenem-resistant cases. No gene significantly predicted mortality. Conclusions: Real-time PCR diagnostic technique combined with epidemiology of antibiotic resistance genes data may be a rapid and effective tool to improve HAP management. Large, multicenter studies are needed in the future to validate the performance of real-time PCR in HAP diagnosis, and appropriate management is also required.
Full article
(This article belongs to the Special Issue Antibiotic Therapy in Respiratory Tract Infections (RTIs))
►▼
Show Figures

Figure 1
Open AccessPerspective
Neonatology: First Exposure to Antibiotics from the Ethical Perspective of Parents, Physicians, and Regulators
by
Iliya Mangarov, Simeon Iliev, Yulian Voynikov, Valentina Petkova, Iva Parvova, Antoaneta Tsvetkova and Irina Nikolova
Antibiotics 2025, 14(9), 936; https://doi.org/10.3390/antibiotics14090936 - 16 Sep 2025
Abstract
Premature infants are an especially vulnerable group that often needs extended intensive care. Prematurity naturally hampers the development of the immune system, significantly increasing the risk of infections. In the Neonatal Intensive Care Unit (NICU), antibiotic treatment is often a crucial, life-saving measure.
[...] Read more.
Premature infants are an especially vulnerable group that often needs extended intensive care. Prematurity naturally hampers the development of the immune system, significantly increasing the risk of infections. In the Neonatal Intensive Care Unit (NICU), antibiotic treatment is often a crucial, life-saving measure. For parents, the birth of a very preterm infant (before 32 weeks of gestation) turns what should be a happy event into a period filled with deep uncertainty and distress. Maintaining hope amid these difficulties relies heavily on maintaining regular communication with and trusting the medical team. Clinical realities in the NICU include a high risk of infection that requires multiple medications, including antibiotics. There is an inverse relationship between gestational age and pharmaceutical exposure. Parents worry about the amount of medication their child receives and the potential long-term effects on development. Over the past thirty years, initiatives such as antimicrobial stewardship programs have worked to reduce antibiotic use and treatment duration in the NICU, emphasizing proper care for premature infants worldwide. This article examines the ethical landscape from the perspectives of three primary stakeholders: parents, healthcare providers, and regulatory bodies. The key ethical question is whether these groups achieve meaningful cooperation or if institutional and professional priorities overshadow clinical practice. In the NICU, decision-making responsibility mainly lies with the medical team, as parents often have limited influence over treatment decisions, and regulatory oversight usually occurs indirectly. This concentration of authority underscores the complex and critical nature of neonatal intensive care.
Full article
(This article belongs to the Special Issue Antibiotic Surveillance and Rational Use in Special Populations: Enhancing Stewardship for Vulnerable Groups)
►▼
Show Figures

Figure 1
Open AccessArticle
Genotypic and Phenotypic Characterization of Antimicrobial Resistance and Virulence in Campylobacter spp. Isolated from Turkeys: Uncovering a Neglected Reservoir in the One Health Context
by
Sebastian Alexandru Popa, Viorel Herman, Khalid Ibrahim Sallam, Emil Tîrziu, Claudiu Andor, Adriana Morar, Mirela Imre, Alexandra Ban-Cucerzan, Răzvan-Tudor Pătrînjan, Alexandra Pocinoc and Kálmán Imre
Antibiotics 2025, 14(9), 935; https://doi.org/10.3390/antibiotics14090935 - 16 Sep 2025
Abstract
Background: Campylobacter spp. are leading foodborne pathogens, with increasing antimicrobial resistance (AMR) posing a critical public health threat. While broiler chickens have been widely studied, turkeys represent an underexplored reservoir. The present study investigates Campylobacter spp. in turkeys, focusing on isolation frequency,
[...] Read more.
Background: Campylobacter spp. are leading foodborne pathogens, with increasing antimicrobial resistance (AMR) posing a critical public health threat. While broiler chickens have been widely studied, turkeys represent an underexplored reservoir. The present study investigates Campylobacter spp. in turkeys, focusing on isolation frequency, resistance, and virulence within the context of One Health. Methods: A total of 182 cecal samples were collected from slaughtered turkeys in Romania. Isolation and identification of Campylobacter jejuni and C. coli followed ISO 10272-1:2017 guidelines. Antimicrobial susceptibility testing was conducted via broth microdilution, and molecular analyses using PCR targeted species identification, resistance determinants, and virulence-associated genes. Results: Campylobacter spp. were detected in 75.8% of samples, with C. jejuni and C. coli accounting for 54.3% and 45.7%, respectively. High resistance rates were observed to ciprofloxacin (89.9%) and tetracycline (85.5%), with moderate resistance to erythromycin and ertapenem. No resistance was found to gentamicin or chloramphenicol. Genotypic analyses confirmed the presence of resistance genes (e.g., tetO, gyrA—Thr-86-Ile mutation, ermB, cmeB) and widespread virulence genes (flaA, cadF, cdtAB, ciaB), supporting phenotypic results. Conclusions: The survey highlights turkeys as a significant but neglected source of resistant and virulent Campylobacter spp., with implications for food safety and public health. The convergence of AMR and virulence aspects calls for integrated surveillance and control strategies across veterinary and human health sectors, supporting the One Health strategy.
Full article
(This article belongs to the Special Issue Virulence, Antimicrobial Resistance and Biofilm Production in Veterinary, Zoonotic and Food-Related Pathogens)
►▼
Show Figures

Figure 1
Open AccessReview
Length and Type of Antibiotic Prophylaxis for Infection Prevention in Adults Patient in the Cardiac Surgery Intensive Care Unit: A Narrative Review
by
Raffaele Barbato, Benedetto Ferraresi, Massimo Chello, Alessandro Strumia, Ilaria Gagliardi, Francesco Loreni, Alessia Mattei, Giuseppe Santarpino, Massimiliano Carassiti, Francesco Grigioni and Mario Lusini
Antibiotics 2025, 14(9), 934; https://doi.org/10.3390/antibiotics14090934 - 16 Sep 2025
Abstract
Background: Infections following cardiac surgery are a significant cause of morbidity and mortality, particularly in intensive care units (ICUs). The role of antibiotic prophylaxis (AP) in preventing surgical site infections (SSIs) and other nosocomial infections is crucial; however, the optimal approach to agent
[...] Read more.
Background: Infections following cardiac surgery are a significant cause of morbidity and mortality, particularly in intensive care units (ICUs). The role of antibiotic prophylaxis (AP) in preventing surgical site infections (SSIs) and other nosocomial infections is crucial; however, the optimal approach to agent selection, dosing, and duration remains controversial. Objective: This narrative review aims to summarise the current evidence and expert recommendations regarding the use of perioperative antibiotic prophylaxis (AP) in adults undergoing cardiac surgery, with a particular focus on intensive care settings, transplant recipients, and adult patients on extracorporeal membrane oxygenation (ECMO). Methods: A comprehensive review of recent literature was conducted, focusing on pharmacokinetic/pharmacodynamic (PK/PD) principles, microbial epidemiology, antimicrobial resistance (AMR), and practical strategies for tailored prophylaxis in high-risk populations. Results: Cefazolin remains the first-line agent for most procedures, with vancomycin or clindamycin reserved for patients who are allergic to β-lactams or who are colonised with MRSA. Redosing is recommended in cases of prolonged surgery or cardiopulmonary bypass. Evidence supports limiting prophylaxis to ≤24 h, with a potential extension to 48 h in select high-risk cases; however, continuation beyond this is discouraged due to the risk of resistance. In heart transplantation, multimodal prophylaxis against bacteria, fungi, and viruses is essential but must be tailored to the individual patient. In the ECMO setting, the current evidence does not support the routine administration of prophylaxis (AP), and therapy should be tailored based on pharmacokinetics (PK)/pharmacodynamics (PD) changes and the clinical context. A multidisciplinary, evidence-based approach to AP in cardiac surgery is essential. Prophylaxis should be patient-specific, microbiologically guided, and limited in duration to reduce the emergence of multidrug-resistant organisms. Integrating antimicrobial stewardship, non-pharmacological measures, and rigorous surveillance is crucial for optimising the prevention of infections in this vulnerable population.
Full article
(This article belongs to the Special Issue Antimicrobial Stewardship and Infection Prevention in Intensive Care Unit)
Open AccessArticle
Impact of the ABxSG Mobile Application on Antibiotic Prescribing: An Interrupted Time Series Study
by
Lai Wei Lee, Shena Yun Chun Lim, Yvonne Peijun Zhou, Shimin Jasmine Chung, De Zhi Chin, Andrea Lay Hoon Kwa and Winnie Hui Ling Lee
Antibiotics 2025, 14(9), 933; https://doi.org/10.3390/antibiotics14090933 - 16 Sep 2025
Abstract
►▼
Show Figures
Background: A point prevalence survey conducted at Singapore General Hospital in 2021 showed 48% of inpatients on antibiotics. We hypothesize that a mobile application, transforming complex antibiotic prescribing information into a succinct and individualized resource, will empower healthcare professionals and improve antibiotic prescriptions.
[...] Read more.
Background: A point prevalence survey conducted at Singapore General Hospital in 2021 showed 48% of inpatients on antibiotics. We hypothesize that a mobile application, transforming complex antibiotic prescribing information into a succinct and individualized resource, will empower healthcare professionals and improve antibiotic prescriptions. Hence, we developed ABxSG using the behavioral design thinking approach (BDTA) to ensure positive user experience and sustained engagement. We aim to evaluate the impact of ABxSG on the proportion of inpatients on antibiotics, antibiotic appropriateness, and the number of antibiotic-related interventions by pharmacists. Methods: ABxSG was launched in March 2023. An interrupted time series analysis was conducted to evaluate its impact on the above outcomes measured using data collected from October 2021 to September 2024. There were 18 data points pre- and post-ABxSG. Results: Following the ABxSG launch, there was an immediate reduction in the proportion of inpatients on antibiotics by 1.66% (p < 0.01), followed by a sustained reduction of 3.12% at 18 months (p < 0.01). Piperacillin-tazobactam appropriateness increased by 2.76% at 1 month (p = 0.11) and further increased by 7.09% at 18 months (p < 0.05). Similarly, ceftriaxone appropriateness increased by 5.74% (p < 0.05) at 1 month and remained above pre-ABxSG levels. There was a significant increase in the number of pharmacist-led interventions for dosing optimization, with 96 more interventions/month at 18 months (p = 0.14). Conclusion: Antimicrobial stewardship teams must remain agile, embrace innovations, and adopt digital technologies to engage and empower clinicians. ABxSG reduced the proportion of inpatients on antibiotics and improved antibiotic prescriptions. The incorporation of BDTA in ABxSG, strong hospital leader support, and strategic planning to promote adoption led to its success.
Full article

Figure 1
Open AccessArticle
Time Trends in Prevalence and Antimicrobial Resistance of Respiratory Pathogens in a Tertiary Hospital in Rome, Italy: A Retrospective Analysis (2018–2023)
by
Fabio Ingravalle, Massimo Maurici, Antonio Vinci, Stefano Di Carlo, Cartesio D’Agostini, Francesca Pica and Marco Ciotti
Antibiotics 2025, 14(9), 932; https://doi.org/10.3390/antibiotics14090932 - 15 Sep 2025
Abstract
Background: The increase in antimicrobial resistance (AMR) is a growing concern for global health. Understanding longitudinal trends in pathogen prevalence and resistance patterns is essential for guiding clinical management and antibiotic stewardship. This retrospective observational study analyzed respiratory microbial isolates collected from 2018
[...] Read more.
Background: The increase in antimicrobial resistance (AMR) is a growing concern for global health. Understanding longitudinal trends in pathogen prevalence and resistance patterns is essential for guiding clinical management and antibiotic stewardship. This retrospective observational study analyzed respiratory microbial isolates collected from 2018 to 2023 in Tor Vergata University Hospital, Rome, Italy. Methods: The data were analyzed through WHOnet 2025 software, and the breakpoint references used are those of EUCAST 2025. The data analyzed included pathogen identification, antibiotic resistance rates, and specimen types. Time-trend analyses were conducted to assess changes in pathogen prevalence and antibiotic resistance rates over time, using the Pearson correlation coefficient and linear regression model. Results: More than 54,000 unique microorganism/drug associations were analyzed, with the majority of them relative to inpatients (over 90%). A. baumannii showed persistently high prevalence and drug resistance to multiple antibiotics. Significant upward resistance trends of K. pneumoniae to multiple antibiotics were observed. Approximately 20% of clinical isolates were fungi, also including some non-albicans Candida (NAC) species, which exhibit intrinsic resistance to azoles. Other microorganisms displayed variable trends in prevalence and resistance profiles. Conclusions: These findings underscore the dynamism of changing patterns of prevalence of microorganisms and their resistance to antimicrobials. They underscore the importance of continuous microbiological surveillance to optimize empirical therapies and guide infection control policies.
Full article
(This article belongs to the Special Issue Epidemiology, Clinical Microbiology and Antimicrobial Therapy: A Shared Effort against Infectious Diseases)
Open AccessArticle
Phenotypic and Molecular Study of Multidrug-Resistant Escherichia coli Isolates Expressing Diverse Resistance and Virulence Genes from Broilers in Tunisia
by
Ghassan Tayh, Fatma Nsibi, Khaled Abdallah, Omar Abbes, Ismail Fliss and Lilia Messadi
Antibiotics 2025, 14(9), 931; https://doi.org/10.3390/antibiotics14090931 - 15 Sep 2025
Abstract
This study investigated the molecular and phenotypic characteristics of antimicrobial resistance in Escherichia coli isolates recovered from the ceca of healthy broilers in Tunisia. A total of 111 E. coli isolates were obtained from chicken samples collected at slaughterhouses and cultured on cefotaxime-supplemented
[...] Read more.
This study investigated the molecular and phenotypic characteristics of antimicrobial resistance in Escherichia coli isolates recovered from the ceca of healthy broilers in Tunisia. A total of 111 E. coli isolates were obtained from chicken samples collected at slaughterhouses and cultured on cefotaxime-supplemented MacConkey agar. All isolates exhibited a multidrug-resistant (MDR) phenotype, and 72.1% were confirmed as extended-spectrum β-lactamase (ESBL) producers. The most frequent β-lactamase gene was blaCTX-M-G1, followed by blaTEM and blaSHV. Carbapenem resistance genes (blaOXA-48 and blaIMP) were detected in 12.6% and 6.3% of isolates, respectively, while six isolates harbored the colistin resistance gene mcr-1. Among the tested virulence genes, fimH, traT, and iutA were the most prevalent, detected in over 70% of isolates. Class 1 integrons were present in 83% of isolates, and class 2 integrons in 39.6%, with gene cassettes encoding resistance to trimethoprim (dfrA) and streptomycin (aadA). These findings highlight the widespread presence of MDR and ESBL-producing E. coli strains with virulence traits and integrons in poultry, underscoring the risk of transmission to humans. This study provides essential data supporting the implementation of integrated surveillance strategies in line with the One Health approach.
Full article
(This article belongs to the Special Issue The Antimicrobial Resistance in the Food Chain)
►▼
Show Figures

Figure 1
Open AccessReview
Cold Plasma as a Revolutionary Antimicrobial Modality: A Multifaceted Weapon Against Antibiotic Resistance
by
Yehia A.-G. Mahmoud, Nehal E. Elkaliny, Farah M. Elshikh, Yara Ashraf, Kamel Metwally, Galal Yahya and Sameha Sherif
Antibiotics 2025, 14(9), 930; https://doi.org/10.3390/antibiotics14090930 - 14 Sep 2025
Abstract
The rise of antibiotic resistance has transformed once-curable infections into urgent global health threats, leaving hospitals with outbreaks, patients with prolonged illnesses, and doctors with limited therapeutic options. The era of antibiotic resistance is no longer a distant concern; it is a pressing
[...] Read more.
The rise of antibiotic resistance has transformed once-curable infections into urgent global health threats, leaving hospitals with outbreaks, patients with prolonged illnesses, and doctors with limited therapeutic options. The era of antibiotic resistance is no longer a distant concern; it is a pressing reality demanding innovative solutions. Among emerging alternatives, cold plasma a partially ionized state of matter enriched with reactive species offers a multi-targeted antimicrobial strategy. Unlike conventional antibiotics, cold plasma disrupts bacterial survival through diverse mechanisms, including membrane rupture, protein and nucleic acid damage, and oxidative stress that overwhelms microbial defenses. This review synthesizes current evidence on the mechanisms of cold plasma, the factors influencing its antimicrobial efficacy, and its applications across healthcare, food safety, and environmental protection. In addition, it highlights the synergistic potential of cold plasma when combined with antibiotics, nanomaterials, or bacteriophages to enhance effectiveness against resistant pathogens. While challenges remain regarding safety validation, standardization, and large-scale application, cold plasma represents a promising non-traditional approach to complement existing therapies. This review not only summarizes recent progress but also outlines future directions, emphasizing its potential role in combating antibiotic resistance.
Full article
(This article belongs to the Special Issue Discovery and Development of Novel Antibacterial Agents—2nd Edition)
►▼
Show Figures

Graphical abstract
Open AccessCase Report
Multidrug-Resistant Escherichia coli Associated with Respiratory and Systemic Infection in a Domestic Rabbit in Romania: First Confirmed Case
by
Vlad Iorgoni, Livia Stanga, Ionica Iancu, Janos Degi, Ionela Popa, Alexandru Gligor, Gabriel Orghici, Bogdan Sicoe, Ioan Cristian Dreghiciu, David Purec, Paula Nistor, Bogdan Florea, Corina Kracunović and Viorel Herman
Antibiotics 2025, 14(9), 929; https://doi.org/10.3390/antibiotics14090929 - 14 Sep 2025
Abstract
Background/Objectives: This report documents the first confirmed case in Romania of fatal pneumonia and septicemia in a domestic rabbit caused by multidrug-resistant Escherichia coli, highlighting both its pathogenic potential and One Health implications. Case Study: An 8-month-old male German Giant Spotted rabbit
[...] Read more.
Background/Objectives: This report documents the first confirmed case in Romania of fatal pneumonia and septicemia in a domestic rabbit caused by multidrug-resistant Escherichia coli, highlighting both its pathogenic potential and One Health implications. Case Study: An 8-month-old male German Giant Spotted rabbit raised on a rural farm under poor husbandry conditions developed acute respiratory distress and died within 48 h. Post-mortem examination revealed severe pulmonary congestion, tracheal inflammation, serofibrinous pericarditis, and systemic vascular lesions. Bacteriological analysis confirmed E. coli from lung, trachea, and bone marrow samples. The isolate demonstrated strong Congo red binding, was confirmed by MALDI-TOF mass spectrometry, and showed resistance to beta-lactams, fluoroquinolones, tetracyclines, sulfonamides, macrolides, and phenicols, remaining susceptible only to aminoglycosides. PCR screening identified virulence genes (fimH, papC, iutA, ompA) linked to adhesion, immune evasion, and iron acquisition, with potential for horizontal gene transfer. Conclusions: This first documented case in Romania emphasizes the clinical threat posed by multidrug-resistant E. coli in rabbits and the importance of early diagnosis, improved biosecurity, and responsible antimicrobial use. The zoonotic and environmental risks in backyard farming underscore the urgent need for integrated surveillance. Alternative control strategies, including phage therapy and probiotics, should be explored to reduce reliance on conventional antibiotics.
Full article
(This article belongs to the Special Issue Veterinary Microbiology and Antimicrobial Resistance—the One Health Approach)
►▼
Show Figures

Graphical abstract
Open AccessArticle
Increase in Penicillin Non-Susceptibility in Group B Streptococci Alongside Rising Isolation Rates—Based on 24 Years of Clinical Data from a Single University Hospital
by
Sunghwan Shin, Dong Hee Whang, Tae-Hyun Um, Chong Rae Cho and Jeonghyun Chang
Antibiotics 2025, 14(9), 928; https://doi.org/10.3390/antibiotics14090928 - 13 Sep 2025
Abstract
Background/Objectives: Streptococcus agalactiae (Group B Streptococci, GBS) is Gram-positive, beta-hemolytic coccus known to be transmitted by vertical transmission in neonates during birth with neonatal sepsis, pneumonia, and meningitis. In adults, particularly the elderly and those with diabetes mellitus, GBS can also cause
[...] Read more.
Background/Objectives: Streptococcus agalactiae (Group B Streptococci, GBS) is Gram-positive, beta-hemolytic coccus known to be transmitted by vertical transmission in neonates during birth with neonatal sepsis, pneumonia, and meningitis. In adults, particularly the elderly and those with diabetes mellitus, GBS can also cause pneumonia and sepsis. Penicillin is the drug of choice, and GBS is generally susceptible to this antibiotic. This study investigates trends in GBS isolation rates and penicillin non-susceptibility over time at a university hospital. Methods: We retrospectively analyzed 24 years (2000–2023) of microbiological data from Ilsan Paik Hospital to investigate trends in GBS isolation and penicillin susceptibility. Isolates were identified and tested using the Vitek 2 system, following CLSI guidelines. WHONET 2023 was used for data aggregation and analysis. Trends were analyzed by dividing the study period into three intervals: Period 1 (2000–2009), Period 2 (2010–2019), and Period 3 (2020–2023). Antimicrobial susceptibility rates for total GBS and PCN-NS GBS (penicillin non-susceptible group B Streptococcus) were compared using chi-square tests. Results: Among 257,884 total isolates, 3003 (1.16%) were GBS, and 29 (0.97%) were PCN-NS. GBS and PCN-NS isolation rates increased significantly across the three periods (p = 0.0001 and p = 0.009, respectively). PCN-NS GBS showed reduced susceptibility to all tested antimicrobials, with no drug showing higher susceptibility compared to total GBS. Conclusions: This study demonstrates a statistically significant rise in both GBS isolation rate and penicillin non-susceptibility over time. Given the emergence of multidrug-resistant GBS strains, susceptibility testing and interdisciplinary collaboration between microbiologists and clinicians are critical to guiding effective antimicrobial therapy and preventing neonatal and adult GBS infections.
Full article
(This article belongs to the Special Issue Advancing and Standardising Antimicrobial Susceptibility and Resistance Detection Methodology)
►▼
Show Figures

Figure 1

Journal Menu
► ▼ Journal Menu-
- Antibiotics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserHighly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Agriculture, Animals, Veterinary Sciences, Antibiotics, Zoonotic Diseases
Animal Diseases in Agricultural Production Systems: Their Veterinary, Zoonotic, and One Health Importance, 2nd Edition
Topic Editors: Ewa Tomaszewska, Beata Łebkowska-Wieruszewska, Tomasz Szponder, Joanna Wessely-SzponderDeadline: 30 September 2025
Topic in
Antibiotics, JPM, Pharmaceuticals, Pharmaceutics, Medicines
Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development
Topic Editors: Inaki F. Troconiz, Victor Mangas Sanjuán, Maria Garcia-Cremades MiraDeadline: 31 October 2025
Topic in
Antibiotics, IJMS, Microbiology Research, Pharmaceuticals, Pharmaceutics, Nanomaterials, Microorganisms
Challenges and Future Prospects of Antibacterial Therapy, 2nd Edition
Topic Editors: Kwang-Sun Kim, Zehra EdisDeadline: 30 November 2026
Topic in
Biomolecules, IJMS, Micro, Molecules, Antibiotics, Nanomaterials, Microorganisms, JFB
Antimicrobial Agents and Nanomaterials—2nd Edition
Topic Editors: Vasco D. B. Bonifácio, Sandra PintoDeadline: 31 December 2026

Conferences
Special Issues
Special Issue in
Antibiotics
Strategies for the Design of Hybrid-Based Antimicrobial Compounds
Guest Editors: Vuyolwethu Khwaza, Sibusiso Alven, Blessing Atim AderibigbeDeadline: 20 September 2025
Special Issue in
Antibiotics
Antibiotic-Associated Dysbiosis and Management
Guest Editor: Yuseok MoonDeadline: 20 September 2025
Special Issue in
Antibiotics
Therapeutic Drug Monitoring of Antibiotics in the Hospital Environment
Guest Editor: Natalia BruckerDeadline: 25 September 2025
Special Issue in
Antibiotics
Innovative Antimicrobial Strategies to Combat Antibiotic Resistance
Guest Editors: Chenxi Huang, Xiaohong WangDeadline: 30 September 2025
Topical Collections
Topical Collection in
Antibiotics
Antimicrobial Prescribing and Antimicrobial Use in Healthcare Settings
Collection Editors: Masayuki Maeda, Yuichi Muraki
Topical Collection in
Antibiotics
Staphylococcus— Molecular Pathogenesis, Virulence Regulation and Antibiotics Resistance
Collection Editor: Ewa Szczuka
Topical Collection in
Antibiotics
Editorial Board Members' Collection Series: Structural Aspects of AMPs and Antimicrobials
Collection Editors: J. Michael Conlon, Marc Maresca, Bong-Jin Lee, Aurélie Tasiemski
Topical Collection in
Antibiotics
Synthetic and Natural Products-Based Antimicrobial and Antiparasitic Agents
Collection Editor: Antonio Eduardo Miller Crotti